Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Financing Activities (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Cash from Financing Activities for 14 consecutive years, with -$31.2 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 583.96% to -$31.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$220.4 million through Dec 2025, down 677.33% year-over-year, with the annual reading at -$220.4 million for FY2025, 677.33% down from the prior year.
  • Cash from Financing Activities hit -$31.2 million in Q4 2025 for Corcept Therapeutics, up from -$46.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $766000.0 in Q4 2023 to a low of -$207.0 million in Q4 2021.
  • Historically, Cash from Financing Activities has averaged -$35.9 million across 5 years, with a median of -$17.5 million in 2022.
  • Biggest five-year swings in Cash from Financing Activities: crashed 31211.5% in 2021 and later skyrocketed 1355.74% in 2023.
  • Year by year, Cash from Financing Activities stood at -$207.0 million in 2021, then soared by 99.97% to -$61000.0 in 2022, then surged by 1355.74% to $766000.0 in 2023, then plummeted by 695.82% to -$4.6 million in 2024, then crashed by 583.96% to -$31.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CORT at -$31.2 million in Q4 2025, -$46.4 million in Q3 2025, and -$102.9 million in Q2 2025.